We estimated the cumulative incidence of persistent infection and the proportion of CIN/AIS attributable to individual carcinogenic HPV genotypes , as well as the proportion of CIN/AIS lesions potentially preventable by a prophylactic 9-valent HPV6/11/16 / 18/31/33 / 45/52/58 vaccine .